Internationally known shoulder surgeon Theodore Blaine, MD, performed first series of procedures
Theodore Blaine, MD, has completed the first series of total shoulder arthroplasty procedures using the Catalyst Stemmed CSR TSA fully convertible system with an ellipsoid humeral head. (Photo: Business Wire)
NAPLES, Fla.--(BUSINESS WIRE)--Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, has announced that internationally recognized orthopedic surgeon Theodore Blaine, MD, has completed the first series of total shoulder arthroplasty procedures using the Catalyst Stemmed CSR TSA fully convertible system with an ellipsoid humeral head.
“Total shoulder arthroplasty continues to advance and convertible stem implants have gained significant momentum. The Catalyst Stemmed CSR TSA is the first fully convertible system to feature an anatomical ellipsoid humeral head,” said Dr. Blaine. “This is an important distinction because the ellipsoid head allows for more accurate restoration of the natural joint kinematics compared to spherical head designs.”
The fully convertible Catalyst Stemmed CSR TSA system, which can convert to a reverse shoulder as needed, received 510(k) clearance in the U.S. in early 2023. Catalyst is now the only company to offer anatomically shaped non-spherical heads in both stemmed and stemless solutions.
“Dr. Blaine is recognized nationally and internationally for his expertise in orthopedics and shoulder surgery. He was a key influencer, along with a select group of highly skilled orthopedic surgeons, in our development of the fully convertible Catalyst Stemmed CSR TSA system with ellipsoid humeral head,” said Carl O’Connell, CEO and president of Catalyst. “Our modern approach to shoulder replacement surgery is focused squarely on designing solutions that better match the patient’s own anatomy, reduce complications and support the needs of surgeons for precision, accuracy and repeatability.”
The implant is currently in limited U.S. release, to be followed by a larger commercial launch later in 2023. In addition to the fully convertible stemmed TSA with ellipsoid humeral head, the Catalyst portfolio includes:
Naples, Florida-based Catalyst OrthoScience was founded in 2014 by orthopedic surgeon Steven Goldberg, MD, who saw the need to make shoulder replacements less invasive, with fewer complications and a more natural-feeling shoulder after surgery. Catalyst is disrupting the traditional approach to shoulder replacement surgery. Our CSRTM Total Shoulder System offers precision and accuracy in shoulder restoration while preserving the patient’s bone and soft tissue. The R1 Reverse Shoulder System is a single-tray arthroplasty system that offers surgeon-targeted implant positioning, a streamlined and versatile system and bone sparing implants. Catalyst has a growing portfolio of patents and pending patents on its distinctive offerings, which are available across the U.S. For more information, visit www.catalystortho.com.
For more information, contact:
Jenni Bowring, Padilla